Statin Therapy and Breast Cancer Recurrence

Article

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara expands on the question of whether statin therapy for breast cancer patients can lower the risk of recurrence and extend relapse-free survival.

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara expands on the question of whether statin therapy for breast cancer patients can lower the risk of recurrence and extend relapse-free survival.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
4 experts in this video
Related Content
Young patients with small-cell lung cancer had less favorable progression-free survival with chemoimmunotherapy.

Chemoimmunotherapy Less Safe, Efficacious in Younger ES-SCLC Population

Tim Cortese
August 16th 2025
Article
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 16th 2025
Podcast
Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC

Russ Conroy
August 16th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 16th 2025
Podcast
In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese
August 16th 2025
Article
An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Roman Fabbricatore
August 16th 2025
Article